Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS015 Combination Therapy in Advanced Solid Tumors
NCT06139211Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Dec 2023
- Primary completion
- May 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of JS015 in Esophageal Squamous Cell Carcinoma (ESCC), gastric cancer (GC), colorectal cancer (CRC), pancreatic cancer (PC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Dec 2023; status: completed.
02
Drugs
JS015
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastric cancer (GC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06139211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139211.